Clinical applications of TNF-α in cancer

Current Opinion in Immunology

Volumn 10, Issue 5, 1998, Pages 573-580

  Lejeune, Ferdy J ^a   Rüegg, Curzio ^a   Liénard, Danielle ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CANCER CHEMOTHERAPY; HUMAN; LIMB PERFUSION; MELANOMA; METASTASIS; REVIEW; SOFT TISSUE SARCOMA;

EID: 0345131696     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(98)80226-4     Document Type: Article

References (42)

1. Old LJ. Tumor necrosis factor (TNF). Science. 230:1985;630-632.
2. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 10:1992;52-60.
3. Sorkin P, Abu-Abid S, Lev D, Gutman M, Aderka D, Halpern P, Setton A, Kudlik N, Bar-On J, Rudich V. Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg. 130:1995;1079-1084.
4. Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 224:1996;756-764.
5. Lienard D, Eggermont AM, Schraffordt Koops H, Kroon BB, Rosenkaimer F, Autier P, Lejeune FJ. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res. 1:1994;21-26.
6. Lejeune FJ, Liénard D, Schraffordt Koops H, Kroon B, Eggermont AMM. Treatment of in-transit melanoma metastases with tumor necrosis factor (TNF-alpha) and chemotherapy administered in isolated limb perfusion. Melanoma Res Suppl. 7:1997;S48.
7. Fraker DL. What is the best regional therapy? Melanoma Res Suppl. 7:1997;S42.
8. Lejeune FJ. High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur J Cancer. 6:1995;1009-1016.
9. Bartlett DL, Ma G, Alexander HR, Libutti SK, Fraker DL. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer. 80:1997;2084-2090.
10. Eggermont AM, Schraffordt Koops H, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 14:1996;2653-2665.
11. Olieman AFT, Pras E, Van Ginkel RJ, Molenaar WM, Schraffordt Koops H, Hoekstra HJ. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys. 40:1998;807-814.
12. Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. of special interest J Clin Oncol. 16:1998;1479-1489 This is the first full report of a phase II study on isolated hepatic perfusion for metastatic cancer confined to the liver. The results show that this procedure is safe and efficient.
13. Oldhafer KJ, Lang H, Frerker M, Moreno L, Chavan A, Flemming P, Nadalin S, Schmoll E, Pichlmayr R. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. Surgery. 123:1998;622-631.
14. Walther MM, Jennings SB, Choyke PL, Andrich M, Hurley K, Linehan WM, Rosenberg SA, Alexander RB. Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. World J Urol. 14:1996;S2-S7.
15. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol. 14:1996;479-489.
16. Renard N, Lienard D, Lespagnard L, Eggermont A, Heimann R, Lejeune F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer. 57:1994;656-663.
17. Renard N, Nooijen PT, Schalkwijk L, De Waal RM, Eggermont AM, Lienard D, Kroon BB, Lejeune FJ, Ruiter DJ. VWF release and platelet aggregation Din human melanoma after perfusion with TNF alpha. J Pathol. 176:1995;279-287.
18. Gerain J, Lienard D, Ewalenko P, Lejeune FJ. High serum levels of TNF-alpha after its administration for isolation perfusion of the limb. Cytokine. 4:1992;585-591.
19. Eggimann P, Chiolero R, Chassot PG, Lienard D, Gerain J, Lejeune F. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest. 107:1995;1074-1082.
20. Zwaveling JH, Maring JK, Clarke FL, van Ginkel RJ, Limburg PC, Hoekstra HJ, Koops HS, Girbes AR. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan. Crit Care Med. 24:1996;765-770.
21. Zwaveling JH, Hoekstra HJ, Maring JK, van Ginkel RJ, Schraffordt Koops H, Smit AJ, Girbes ARJ. Renal function in cancer patients treated with hyperthermic isolated limb perfusion with recombinant tumor necrosis factor-alpha and melphalan. Nephron. 76:1997;146-152.
22. Zwaveling JH, Maring JK, Girbes ARJ, Schraffordt Koops H. Side effects of cancer treatment with recombinant human tumour necrosis factor alpha: a new challenge for the intensive care unit. Clin Intensive Care. 8:1997;142-150.
23. Sleijfer S, van Ginkel RJ, van der Mark TW, Hoekstra HJ, Zwaveling JH, Schraffordt Koops H, Mulder NH. Effects of hyperthermic isolated limb perfusion with Tumor Necrosis Factor-alpha and melphalan on pulmonary function assessments. J Immunother. 20:1997;202-207.
24. Gérain J, Liénard D, Pampallona S, Baumgartner M, Rüegg C, Buurman WA, Eggermont A, Lejeune FJ. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion. of special interest Cytokine. 9:1997;1034-1042 Isolated limb perfusion with TNF-α results in the release of soluble TNF receptors (sTNFRs). This paper shows that sTNFRII plays a limited protective role in inhibiting activity of circulating TNF-α, when sTNFRII concentration is in excess over circulating TNF-α concentrations.
25. Aderka D, Sorkine P, Abu-Abid S, Lev D, Setton A, Cope AP, Wallach D, Klausner J. Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. of special interest J Clin Invest. 101:1998;650-659 This reports observations taken from cases of isolated limb perfusion that provide a basis for understanding the interplay of TNF-α and its receptors in septic shock.
26. Schenk S, Lienard D, Gerain J, Baumgartner M, Lejeune FJ, Chiquet-Ehrismann R, Ruegg C. Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumors. Int J Cancer. 63:1995;665-672.
27. Stam TC, Jongen-Lavrencic M, Eggermont AMM, Swaak AJG. Effects of isolated limb perfusion with tumour necrosis factor-alpha on the function of monocytes and T lymphocytes in patients with cancer. Eur J Clin Invest. 26:1996;1085-1091.
28. Waanders GA, Rimoldi D, Liénard D, Carrel S, Lejeune FJ, Dietrich PY, Cerottini JC, Romero P. Melanoma-reactive human cytotoxic lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line. Clin Cancer Res. 3:1997;685-696.
29. Nooijen PT, Eggermont AM, Verbeek MM, Schalkwijk L, Buurman WA, de Waal RM, Ruiter DJ. Transient induction of E-selectin expression following TNF alpha-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific. J Immunother. 19:1996;33-44.
30. Olieman AF, van Ginkel RJ, Hoekstra HJ, Mooyaart EL, Molenaar WM, S. Koops H. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Annals Surg Oncology. 4:1997;64-69.
31. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh D. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164.
32. Rüegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. of outstanding interest Nat Med. 4:1998;408-414 This paper demonstrates a novel mechanism by which cytokines control integrin-mediated cell adhesion. TNF-α and IFN-γ deactivate αVβ3 integrin on angiogenic endothelial cells, leading to a lack of adhesion and apoptosis.
33. Merryman P, Tannenbaum SH, Gralnick HR, Yu K, Arnold WS, Alexander HR, Fraker D, Horne MR. Fibrinolytic and coagulant responses to regional limb perfusions of tumor necrosis factor, interferon-gamma, and/or melphalan. Thromb Haemost. 77:1997;53-56.
34. Michelmann I, Bockmann D, Nurnberger W, Eckhofdonovan S, Burdach S, Gobel U. Thrombocytopenia and complement activation under recombinant tnf-alpha/ifn-gamma therapy in man. Ann Hematol. 74:1997;179-184.
35. Robins HI, D'Oleire F, Grosen E, Spriggs E. Rationale and clinical status of 41.8 degrees C systemic hyperthermia tumor necrosis factor, and melphalan for neoplastic disease. Anticancer Res. 17:1997;2891-2894.
36. Dubois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Dinarello C, Kappler K, Ronayne L, Rand W, Atkins MB. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol. 15:1997;1052-1062.
37. Kettelhack C, Hohenberger P, Schlag PM. Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor. Langenbecks Arch Chir. 113:1996;127-129.
38. Di Filippo F, Anza M, Rossi CR, Cavaliere F, Schiratti M, Vecchiato A, Lise M, Cavaliere R. Hyperthermic antiblastic perfusion with TNF alpha and L PAM in patients with stage II, IIIA and IIIAB limb melanoma. Melanoma Res. 7:1997;S32-S33.
39. Gutman M, Lev-Chelouche D, Abu-Abeid S, Inbar M, Klausner JM. Isolated limb perfusion (ILP) with tumour necrosis factor (TNF) and melphalan for locally advanced malignant melanoma [abstract]. Eur J Surg Oncol. 24:1998;213.
40. Santinami M, Deraco M, Azzarelli A, Cascinelli F, Chiti A, Costagli V, Inglese MG, Manzi R, Quagliolo V, Rebuffoni G, et al. Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan. Tumori. 82:1996;579-584.
41. Gutman M, Inbar M, Lev-Shlush D, Abu-Abid S, Mozes M, Chaitchik S, Meller I, Klausner JM. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer. 79:1997;1129-1137.
42. Di Filippo F, Rossi CR, Vaglini M, Azzarelli A, Anza M, Santinami M, Lise M, Cavaliere F, Giannarelli D, Quagliuolo V, et al. Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study. J Immunother. 1998;. in press.